Skip to content

Sarepta Therapeutics’ CEO Chris Garabedian Talks About FDA Accelerated Approval For Orphan Drug Eteplirsen (November 27, 2012)

November 28, 2012

       Tuesday, November 27, 2012, Sarepta Therapeutics’ CEO and President, Chris Garabedian, presents at the 24th Annual Piper Jaffray Healthcare Conference. Mr. Garabedian discusses the feasibility of asking the FDA for Accelerated Approval for orphan drug Eteplirsen for Duchenne Muscular Dystrophy (DMD).    

         Sarepta Therapeutics is scheduled to present at the Deutsche Bank 2012 dbAccess BioFEST Conference in Boston, Massachusetts, on Tuesday, December 4, 2012, at 7:50 AM Eastern Time. Chris Garabedian will be the presenter. 

References 

***  MassHighTech.com November 27, 2012 article titled, “Sarepta’s DMD strategy – develop 20 similar drugs”. 

Copyright © 2012-2013, Orphan Druganaut Blog.  All rights reserved.

Advertisements
Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: